Maximilian Merz

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E. K., Uta Bertsch, Jan Dürig et al. · Leukemia · 2015 · 141 citations

Medicine, Oncology, Pharmacotherapy +14

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

Maximilian Merz, Thomas Hielscher, Benedikt Wagner et al. · Leukemia · 2014 · 124 citations

Medicine, Oncology, Radiology +14

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents

Maximilian Merz, Kai Neben, Marc‐Steffen Raab et al. · Annals of Oncology · 2013 · 76 citations

Medicine, Hematology, Oncology +17

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Maximilian Merz, Hans Salwender, Mathias Haenel et al. · Haematologica · 2015 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

EASIX for prediction of survival in lower-risk myelodysplastic syndromes

Almuth Maria Anni Merz, Ulrich Germing, Guido Kobbe et al. · Blood Cancer Journal · 2019 · 69 citations · Full text

Medicine, Hematology, Internal Medicine +17